| Literature DB >> 31756965 |
Eugenie Mussard1, Annabelle Cesaro1, Eric Lespessailles1,2,3, Brigitte Legrain4, Sabine Berteina-Raboin5, Hechmi Toumi1,2,3.
Abstract
Traditionally, Andrographis paniculata has been used as an herbal remedy for lung infection treatments. Its leaves contain a diterpenoid labdane called andrographolide responsible for a wide range of biological activities such as antioxidant, anti-inflammatory, and anti-cancer properties. This manuscript is a brief review of the antioxidant mechanisms and the regulation of the Nrf2 (nuclear factor (erythroid-derived 2)-like 2) signaling pathway by andrographolide.Entities:
Keywords: Andrographis paniculata; Nrf2; andrographolide; oxidative stress
Year: 2019 PMID: 31756965 PMCID: PMC6943416 DOI: 10.3390/antiox8120571
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Figure 1Andrographis paniculata.
Figure 2Compounds found in the leaves of Andrographis paniculata.
Main effects of andrographolide on Nrf2 (nuclear factor (erythroid-derived 2)-like 2) pathway in vitro. Symbols: “↗” for an increase, “↘” for a decrease, and “-” for not communicated. ARE: antioxidant response element, Keap-1: Kelch-like ECH-associated protein 1, GSH: reduced glutathione, NOX: NADPH oxidase, SOD: superoxide dismutase, CAT: catalase.
| Treatment(s) | Nrf2 mRNA | Nrf2 Protein | Nrf2 Translocation | Nrf2 Phosphorylation | Nrf2 Binding Activity to ARE Sequence | Nrf2 Inhibitor (Keap-1) | Nrf2 Turnover and Ubiquitination | Nrf2 Targets | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| 2.5, 5, and 7.5 µM for 16 h followed by incubation with TNF-α (1 ng/mL) for an additional 6 h | - | - | ↗ | - | ↗ | - | - | HO-1 mRNA and protein ↗ | [ |
| 7.5 µM andrographolide for 16 h | - | - | - | - | - | - | - | HO-1 protein ↗ | [ |
| 30 µM andrographolide with 2% cigarette smoke extract | - | - | ↗ | - | ↗ | - | - | GSH ↗; expression of antioxidants GCLM, GCLC, GR, GPx-2, and HO-1 ↗ | [ |
| 30 µM for 24 h | - | - | ↗ | - | ↗ | - | - | ↗ ARE-sensitive genes including HO-1, GCLC, GCLM, SRXN1, TXNRD1, and GSR but not NQ01 | [ |
| 1, 5, 7.5, and 10 µM | - | ↗ | ↗ | - | ↗ | No effect | - | HO-1 promoter activity and mRNA ↗ | [ |
| 7.5 µM andrographolide for 24 h | - | - | ↗ | - | - | - | - | HO-1 mRNA and protein ↗; GCLM mRNA and protein ↗ but not GCLC | [ |
| 5 and 10 µM | - | - | ↗ | p-Nrf2 (ser40) ↗ | - | - | - | HO-1 mRNA and protein ↗ | [ |
| 1, 5, 10, 30, and 50 µM | 50 µM for 24h ↗ | 1–50 µM for 1h ↗, and 50 µM for 30 min to 24 h ↗ | 50 µM for 30 min to 24 h ↗ | no effect on p-Nrf2 (ser40) | - | No effect | ↘ | HO-1 mRNA (2 h with 50 µM) and protein (4 h with 50 µM) ↗ | [ |
| 1, 5, and 10 µM | - | ↗ | ↗ | - | ↗ | No effect | - | HO-1 mRNA and protein ↗ | [ |
|
| - | ↗ | - | - | - | - | - | HO-1 protein ↗, Nox2, Nox4, and P47phox mRNA ↘ | [ |
| H2O2 0.1 mmol/L and andrographolide 0.625 and 2.5 µg/mL | - | ↗ | - | - | - | - | - | Activities of SOD and CAT ↗; SOD and CAT proteins ↗ | [ |
| β-amyloid (Aβ) peptide 10 µM and andrographoldie 20 µM for 1 h | ↗ | ↗ | - | - | - | - | - | - | [ |
| 1, 7.5, 15, 30, 60, and 120 µM | - | ↗ | - | - | ↗ | At low concentration, function of the CUL3-RBX1-KEAP-1 E3 ubiquitin ligase via Cys151 ↘ at high concentration action via a mechanism independent of Cys151 in KEAP-1 | ↗ | - | [ |
| 20 and 40 µM | ↗ | ↗ | ↗ | - | - | - | - | HO-1 protein ↗; GSH protein ↗; GCLC/GCLM/GS mRNAs and proteins ↗; GR mRNA, protein, and activity ↗ but GPx1 mRNA and total GPx activity ↘ | [ |
Main effects of andrographolide on Nrf2 pathway in vivo, Symbols: “↗” for an increase, “↘” for a decrease, and “-” for not communicated.
| Model(s) | Treatment(s) | Nrf2 mRNA | Nrf2 Protein | Nrf2 Translocation | Nrf2 Binding Activity to ARE Sequence | Nrf2 Inhibitor (Keap-1) | Nrf2 Targets | Ref. |
|---|---|---|---|---|---|---|---|---|
| Sprague–Dawley rats (liver, heart, and kidneys) | 30 or 50 mg/kg/day for 5 consecutive days, intragastrical | - | - | ↗ (liver) | ↗ (liver) | - | SOD activity ↗ (liver, kidney, heart, and red blood cells); CAT activity ↗ (heart); GSH peroxidase activity ↗ (kidney); GSH reductase ↗ (kidney, heart, and red blood cells); GSH S-transferase ↗ (liver); GSH protein ↗ (heart); antioxidant proteins (SOD1, GST Ya, GST Yb, HO-1, GCLC, and GCLM) ↗ (liver, kidney, and heart); mRNA (GCLC, GCLM, GST Ya/Yb, SOD1, and HO-1) ↗ (liver and kidney) | [ |
| Wistar rats | 0.1 mg/kg, intraperitoneal (6 h) | - | - | - | - | - | HO-1 protein ↗ (brains) | [ |
| BALB/c mice | 5 or 10 mg/kg, intraperitoneal (1 and 24 h) | - | - | ↗ (lung) | - | mRNA ↘ (lung) | HO-1, GR, GCLM, GPx-2, and NQO1 (mRNA) ↗ | [ |
| BALB/c mice | LPS/GalN (1 h) followed by andrographolide (2.5, 5, or 10 mg/kg), intraperitoneal (8 h) | - | ↗ (liver) | - | - | - | HO-1 protein ↗ (liver) | [ |
| C57BL/6 mice | Acetaminophen (orally) every day for 6 weeks followed by andrographolide (20 or 40 mg/kg, orally) treatment every day at 2 weeks after acetaminophen administration | - | - | ↗ (liver) | - | - | ANDRO reversed the decreased hepatic expression of GCLC, GCLM and HO-1 mRNA expression induced by acetaminophen. Co-treatment with ANDRO (40 mg/kg) ↗ NQO1 mRNA | [ |
| C57BL/6 mice | Streptozotocin (intraperitoneal injection) for 5 consecutive days followed by andrographolide (1, 10, or 20 mg/kg/day) for 12 weeks by intragastric gavage | ↗ (heart) | - | - | - | - | SOD activity ↗; MDA and 4-HNE ↘; Nox2, Nox-4, p47phox, Nrf2, and HO-1 mRNA ↘ | [ |
| Balb/c mice | Toluene diisocyanate treatment (dermally and intranasally) for asthma induction with andrographolide treatment (0.1, 0.5, or 1 mg/kg, prophylatic regimen) | - | ↗ (lung) | - | - | - | HO-1 protein ↗ (1 mg/kg, lung) | [ |